Vernalis plc (VER) Earns “Buy” Rating from Canaccord Genuity
Vernalis plc (LON:VER)‘s stock had its “buy” rating reiterated by research analysts at Canaccord Genuity in a research report issued on Thursday. They currently have a GBX 88 ($1.09) price target on the stock. Canaccord Genuity’s price target suggests a potential upside of 164.66% from the stock’s previous close.
Other equities analysts also recently issued reports about the company. N+1 Singer reissued a “hold” rating and issued a GBX 37 ($0.46) target price on shares of Vernalis plc in a research report on Thursday. Panmure Gordon cut their target price on Vernalis plc from GBX 76 ($0.94) to GBX 65 ($0.81) and set a “buy” rating on the stock in a research report on Thursday. Finally, Stifel Nicolaus upped their target price on Vernalis plc from GBX 94 ($1.17) to GBX 99 ($1.23) and gave the company a “buy” rating in a research report on Tuesday, September 6th. One research analyst has rated the stock with a hold rating and three have given a buy rating to the stock. Vernalis plc currently has an average rating of “Buy” and a consensus price target of GBX 69 ($0.86).
Vernalis plc (LON:VER) opened at 34.0625 on Thursday. Vernalis plc has a 52-week low of GBX 31.00 and a 52-week high of GBX 72.75. The stock’s market capitalization is GBX 179.24 million. The company’s 50-day moving average price is GBX 37.51 and its 200 day moving average price is GBX 41.75.
In related news, insider Carol Ferguson purchased 28,000 shares of the firm’s stock in a transaction that occurred on Friday, September 30th. The shares were purchased at an average cost of GBX 41 ($0.51) per share, with a total value of £11,480 ($14,241.41). Also, insider David Mackney sold 27,233 shares of the firm’s stock in a transaction dated Wednesday, October 12th. The shares were sold at an average price of GBX 39 ($0.48), for a total transaction of £10,620.87 ($13,175.62).
About Vernalis plc
Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.
Receive News & Stock Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related stocks with our FREE daily email newsletter.